ArticleScientific reports2021
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.Journal of clinical medicine · 2026Review
- Identification and validation of lymphangiogenesis-related genes for predicting acute myeloid leukemia prognosis: insights from bulk RNA sequencing and single-cell RNA sequencing analyses.Clinical and experimental medicine · 2026Article
- Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.Journal of internal medicine · 2025Review
- Feasible and Rapid Screening ofDiagnostics (Basel, Switzerland) · 2025Article
- Anti-proliferative effects of a polyherbal formulation on HL-60, HCT-116, and HeLa cell lines: a docking simulation and response surface design-aided study.Frontiers in chemistry · 2025Article
- Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.International journal of molecular sciences · 2024Review
- Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.Annals of hematology · 2024Article
- A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.Frontiers in oncology · 2024Article
- Advances in the pharmacological management of acute myeloid leukemia in adults.Expert opinion on pharmacotherapy · 2022Article
- Unified classification and risk-stratification in Acute Myeloid Leukemia.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 15 institutions in 3 countries.
Marta LiburaMedical University of Warsaw, Warsaw, Poland. marta.libura@gmail.com.
Emilia BialopiotrowiczInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Sebastian GiebelMaria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Agnieszka WierzbowskaMedical University of Lodz, Lodz, Poland.
Gail J RobozWeil Cornell Medical College, New York, NY, USA.
Beata Piatkowska-JakubasFaculty of Medicine, Jagiellonian University, Cracow, Poland.
Marta PawelczykMedical University of Warsaw, Warsaw, Poland.
Patryk GorniakInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Katarzyna BorgInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Magdalena WojtasInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Izabella FlorekFaculty of Medicine, Jagiellonian University, Cracow, Poland.
Karolina MatiakowskaFaculty of Medicine, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
Bozena JazwiecMedical University of Wroclaw, Wroclaw, Poland.
Iwona SolarskaInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Monika Noyszewska-KaniaInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Karolina PiechnaInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Magdalena ZawadaFaculty of Medicine, Jagiellonian University, Cracow, Poland.
Sylwia CzekalskaFaculty of Medicine, Jagiellonian University, Cracow, Poland.
Zoriana SalamanczukHopitaux Universitaires de Geneve, Geneve, Switzerland.
Karolina KarabinMedical University of Warsaw, Warsaw, Poland.
Katarzyna WasilewskaMedical University of Lodz, Lodz, Poland.
Monika PaluszewskaMedical University of Warsaw, Warsaw, Poland.
Elzbieta UrbanowskaMedical University of Warsaw, Warsaw, Poland.
Justyna Gajkowska-KulikNicolaus Copernicus Municipal Specialist Hospital, Torun, Poland.
Grazyna SemenczukDr Biziel University Hospital, Bydgoszcz, Poland.
Justyna RybkaMedical University of Wroclaw, Wroclaw, Poland.
Tomasz WrobelMedical University of Wroclaw, Wroclaw, Poland.
Anna EjdukInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Dariusz KataMedical University of Silesia, Katowice, Poland.
Sebastian GrosickiDepartment of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland.
Tadeusz RobakMedical University of Lodz, Lodz, Poland.
Agnieszka PlutaMedical University of Lodz, Lodz, Poland.
Agata KominekLaboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland.
Katarzyna PiwockaLaboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland.
Karolina PyziakRyvu Therapeutics S.A., Cracow, Poland.
Agnieszka Sroka-PoradaRyvu Therapeutics S.A., Cracow, Poland.
Anna WrobelRyvu Therapeutics S.A., Cracow, Poland.
Agnieszka PrzybylowiczRyvu Therapeutics S.A., Cracow, Poland.
Marzena WojtaszewskaDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Krzysztof LewandowskiDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Lidia GilDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Agnieszka PiekarskaDepartment of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
Wanda KnopinskaDepartment of Hematology, Hospital of the Ministry of Internal Affairs and Administration with Regional Oncology Center, Olsztyn, Poland.
Lukasz BolkunDepartment of Hematology, Medical University of Bialystok, Bialystok, Poland.
Krzysztof WarzochaInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Kazimierz KuliczkowskiMedical University of Wroclaw, Wroclaw, Poland.
Tomasz SachaFaculty of Medicine, Jagiellonian University, Cracow, Poland.
Grzegorz BasakMedical University of Warsaw, Warsaw, Poland.
Wieslaw Wiktor JedrzejczakMedical University of Warsaw, Warsaw, Poland.
Jerzy HolowieckiMaria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Przemysław JuszczynskiInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Olga HausFaculty of Medicine, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
Instytut Hematologii i Transfuzjologi · PLMedical University of Warsaw · PLJagiellonian University · PLMedical University of Lodz · PLWroclaw Medical University · PLNicolaus Copernicus University · PLPoznan University of Medical Sciences · PLInstytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLMedical University of Silesia · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLGdańsk Medical University · PLHôpital Beau-Séjour · CHMedical University of Białystok · PLNewYork–Presbyterian Hospital · USUniversity of Bydgoszcz · PL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) genes occur in about 20% patients with acute myeloid leukemia (AML), leading to DNA hypermethylation and epigenetic deregulation. We assessed the prognostic significance of IDH1/2 mutations (IDH1/2
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsAdolescentAdultAgedAntineoplastic AgentsCladribineCytarabineDaunorubicinHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMiddle AgedPharmacogenomic VariantsPolandRandomized Controlled Trials as TopicRetrospective StudiesAntineoplastic AgentsCladribineCytarabineDaunorubicinIDH2 protein, humanIsocitrate Dehydrogenase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.